Pheochromocytoma

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 2, Issue , 2010, Pages 1990-2018

  Pacak, Karel ^a   Timmers, Henri J L M ^b   Eisenhofer, Graeme ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879553876     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00109-X     Document Type: Chapter

References (265)

1. WM Manger and RW Gifford (2002) Pheochromocytoma. J Clin Hypertens 4(1), 62-72.
2. K Pacak, WM Linehan, G Eisenhofer, et al. (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134(4), 315-329.
3. FM Brouwers, JW Lenders, G Eisenhofer, et al. (2003) Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord 4(2), 121-128.
4. MG Sutton, SG Sheps and JT Lie (1981) Prevalence of clinically unsuspected pheochromocytoma, review of a 50-year autopsy series. Mayo Clin Proc 56(6), 354-360.
5. EL Bravo and R Tagle (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4), 539-553.
6. K Pacak, G Eisenhofer, JA Carrasquillo, et al. (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38(1), 6-8.
7. K Pacak, G Eisenhofer, JA Carrasquillo, et al. (2002) Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. Ann N Y Acad Sci 970 170-176.
8. AM Sawka, R Jaeschke, RJ Singh, et al. (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88(2), 553-558.
9. JW Lenders, K Pacak, MM Walther, et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11), 1427-1434.
10. JH Kaouk, S Matin, EL Bravo, et al. (2002) Laparoscopic bilateral partial adrenalectomy for pheochromocytoma. Urology 60(6), 1100-1103.
11. R Munver, JJ Del Pizzo and RE Sosa (2003) Adrenal-preserving minimally invasive surgery: the role of laparoscopic partial adrenalectomy, cryosurgery, and radiofrequency ablation of the adrenal gland. Curr Urol Rep 4(1), 87-92.
12. HP Neumann, B Bausch, SR McWhinney, et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19), 1459-1466.
13. O Kuchel (1983) Pheochromocytoma. J Genest, O Kuchel, P Hamet, et al., (Eds) Hypertension: Physiopathology and Treatment ed 2 New York: McGraw-Hill 947-963.
14. L Pick (1912) Das Ganglioma embryonale sympathicum (Sympathoma embryonale), eine typisch bosartige Geschwulstform des sympathischen Nervensystems. Klin Wochenschr 49 16-22.
15. F Frankel (1886) Ein fall von doppelseitigem, vollig latent verlaufenden Nebennieren tumor und gleichzeitiger Nephritis mit Veranderungen am Circulationsapparat und Retinitis. Virchows Arch 103 244-263.
16. H Alezais and A Peyron (1908) Un groupe nouveau de tumeurs epitheliales: les paraganglions. Compte Rend Soc Biol (Paris) 65 745-747.
17. M L’Abbe, J Tinel and A Doumer (1922) Crises solaires et hypertension paroxystique en rapport avec une tumeur surrenale. Bull Mem Soc Med Hop (Paris) 46 982-990.
18. WM Manger and RW Gifford (1996) Clinical and Experimental Pheochromocytoma. ed 2 Cambridge, MA: Blackwell Science
19. CH Mayo (1927) Paroxysmal hypertension with tumor of retroperitoneal nerve. Report of case. JAMA 89 1047-1050.
20. CB Rabin (1929) Chromaffin cell tumor of the suprarenal medulla (pheochromocytoma). Arch Pathol 7 228-243.
21. HM Kelly, MC Piper and RE Wilder (1936) Case of paroxysmal hypertension with paraganglioma of the right suprarenal gland. Mayo Clin Proc 11 65-70.
22. US von Euler (1946) Presence of a substance with sympathin E properties in spleen extracts. Acta Physiol Scand 11 168-186.
23. US von Euler (1946) The presence of a sympathomimetic substance in extracts of mammalian heart. J Physiol 105 38-44.
24. P Holtz, K Credner and G Kroneberg (1947) Uber das sympathicomimetische pressorische Prinizip des Harns (“Urosympathin”). Arch Exp Pathol Pharmakol 204 228-243.
25. P Holton (1949) Noradrenaline in tumors of the adrenal medulla. J Physiol 108 525-529.
26. WF Kvale, GM Roth, WM Manger, et al. (1956) Pheochromocytoma. Circulation 14 622-630.
27. FH Epstein and RD Eckhoff (1967) The epidemiology of high blood pressure—geographic distributions and etiologic factors. J Stamler, R Stamler, TN Pullman,(Eds) The epidemiology of hypertension New York: Grune and Stratton 155-166.
28. LB Page (1976) Epidemiologic evidence on the etiology of human hypertension and its possible prevention. Am Heart J 91(4), 527-534.
29. W McBride, C Ferrario and PA Lyle (2003) Hypertension and medical informatics. J Natl Med Assoc 95(11), 1048-1056.
30. K Pacak, GP Chrousos, CA Koch, et al. (2001) Pheochromocytoma: progress in diagnosis, therapy, and genetics. A Margioris, GP Chrousos,(Eds) Adrenal Disorders ed 1 Totowa: Humana Press 479-523.
31. G Eisenhofer, DS Goldstein, IJ Kopin, et al. (2003) Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14(3), 193-212.
32. S Udenfriend (1966) Tyrosine hydroxylase. Pharmacol Rev 18(1), 43-51.
33. G Eisenhofer, DS Goldstein (2004) Peripheral dopamine systems. D Robertson, P Low, G Burnstock, et al., (Eds) Primer on the Autonomic Nervous System San Diego: Elsevier in press
34. J Axelrod (1966) Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 18(1), 95-113.
35. RG Johnson Jr (1988) Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol Rev 68(1), 232-307.
36. WJ Brown, L Barajas, J Waisman, et al. (1972) Ultrastructural and biochemical correlates of adrenal and extra-adrenal pheochromocytoma. Cancer 29(3), 744-759.
37. T Nagatsu (1995) Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem 30 15-35.
38. JP Henry, C Sagne, C Bedet, et al. (1998) The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int 32(3), 227-246.
39. DT O’Connor, H Wu, BM Gill, et al. (1994) Hormone storage vesicle proteins, transcriptional basis of the wide-spread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular. Ann N Y Acad Sci 733 36-45.
40. T Nagatsu and L Stjarne (1998) Catecholamine synthesis and release. Overview. Adv Pharmacol 42 1-14.
41. G Eisenhofer (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91(1), 35-62.
42. G Eisenhofer, TT Huynh, M Hiroi, et al. (2001) Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2(3), 297-311.
43. G Eisenhofer, H Keiser, P Friberg, et al. (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83(6), 2175-2185.
44. G Eisenhofer, B Rundqvist, A Aneman, et al. (1995) Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 80 3009-3017.
45. G Eisenhofer, A Aneman, D Hooper, et al. (1996) Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66 1565-1573.
46. HP Neumann, DP Berger, G Sigmund, et al. (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329(21), 1531-1538.
47. HP Neumann, BU Bender, A Januszewicz, et al. (1997) Inherited pheochromocytoma. Adv Nephrol Necker Hosp 27 361-376.
48. EL Bravo, RC Tarazi, FM Fouad, et al. (1981) Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 305(11), 623-626.
49. EL Bravo and RW Gifford Jr (1993) Pheochromocytoma. Endocrinol Metab Clin North Am 22(2), 329-341.
50. RW Gifford Jr, EL Bravo and WM Manger (1985) Diagnosis and management of pheochromocytoma. Cardiology 72(Suppl 1), 126-130.
51. PG Bouloux and M Fakeeh (1995) Investigation of phaeochromocytoma. Clin Endocrinol (Oxf) 43(6), 657-664.
52. WM Manger Jr, GRW (1977) Pheochromocytoma. New York: Springer-Verlag
53. PF Plouin, P Degoulet, A Tugaye, et al. (1981) [Screening for phaeochromocytoma: in which hypertensive patients? A semilogical study of 2585 patients, including 11 with phaeochromocytoma (author's transl)]. Nouv Presse Med 10(11), 869-872.
54. AL Steiner, AD Goodman and SR Powers (1968) Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47(5), 371-409.
55. DA Bittar (1979) Innovar-induced hypertensive crises in patients with pheochromocytoma. Anesthesiology 50(4), 366-369.
56. M Barancik (1989) Inadvertent diagnosis of pheochromocytoma after endoscopic premedication. Dig Dis Sci 34(1), 136-138.
57. RT Schorr and SN Rogers (1987) Intraoperative cardiovascular crisis caused by glucagon. Arch Surg 122(7), 833-834.
58. T Jan, BE Metzger and G Baumann (1990) Epinephrine-producing pheochromocytoma with hypertensive crisis after corticotropin injection. Am J Med 89(6), 824-825.
59. LB Page, JW Raker and FR Berberich (1969) Pheochromocytoma with predominant epinephrine secretion. Am J Med 47(4), 648-652.
60. RF Cook and D Katritsis (1990) Hypertensive crisis precipitated by a monoamine oxidase inhibitor in a patient with phaeochromocytoma. BMJ 300(6724), 614.
61. JB Young and L Landsberg (1998) Catecholamines and the Adrenal Medulla. JD Wilson, DW Foster,(Eds) William's Textbook of Endocrinology 9 665-728.
62. HJ Timmers, A Kozupa, G Eisenhofer, et al. (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92(3), 779-786.
63. JA Colwell (1969) Inhibition of insulin secretion by catecholamines in pheochromocytoma. Ann Intern Med 71(2), 251-256.
64. ER Edelman, CA Stuenkel, JD Rutherford, et al. (1992) Diabetic ketoacidosis associated with pheochromocytoma. Cleve Clin J Med 59(4), 423-427.
65. AF Stewart, JL Hoecker, LE Mallette, et al. (1985) Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism. Ann Intern Med 102(6), 776-779.
66. H Heath 3rd and AJ Edis (1979) Pheochromocytoma associated with hypercalcemia and ectopic secretion of calcitonin. Ann Intern Med 91(2), 208-210.
67. RF Spark, PB Connolly, DS Gluckin, et al. (1979) ACTH secretion from a functioning pheochromocytoma. N Engl J Med 301(8), 416-418.
68. G Viale, P Dell’Orto, E Moro, et al. (1985) Vasoactive intestinal polypeptide-, somatostatin-, and calcitonin- producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings. Cancer 55(5), 1099-1106.
69. M Bornemann, SC Hill and GS Kidd 2nd (1986) Lactic acidosis in pheochromocytoma. Ann Intern Med 105(6), 880-882.
70. A Salahuddin, T Rohr-Kirchgraber, R Shekar, et al. (1997) Interleukin-6 in the fever and multiorgan crisis of pheochromocytoma. Scand J Infect Dis 29(6), 640-642.
71. HT Stelfox, AK Stewart, D Bailey, et al. (1997) Castleman's disease in a 44-year-old male with neurofibromatosis and pheochromocytoma. Leuk Lymphoma 27(5–6), 551-556.
72. G Stenstrom and K Svardsudd (1986) Pheochromocytoma in Sweden 1958–1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220(3), 225-232.
73. HD Moon, AA Koneff, CC Li, et al. (1956) Pheochromocytomas of adrenals in male rats chronically injected with pituitary growth hormone. Proc Soc Exp Biol Med 93 74-77.
74. M Esler, S Julius, A Zweifler, et al. (1977) Mild high-renin essential hypertension, neurogenic human hypertension? N Engl J Med 296(8), 405-411.
75. EL Bravo, RC Tarazi, RW Gifford, et al. (1979) Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301(13), 682-686.
76. O Kuchel (1985) Pseudopheochromocytoma. Hypertension 7(1), 151-158.
77. O Kuchel (2004) New Insights Into Pseudopheochromocytoma and Emotionally Provoked Hypertension. GA Mansoor,(Eds) Secondary Hypertension Totowa: Humana Press
78. WB White and LH Baker (1986) Episodic hypertension secondary to panic disorder. Arch Intern Med 146(6), 1129-1130.
79. IH Page (1935) A syndrome simulating diencephalic stimulation occurring in patients with essential hypertension. Am J Med Sci 190 9-14.
80. EE Lack (1990) Pathology of the Adrenal Glands. LM Roth,(Eds) Contemporary Issues in Surgical Pathology New York: Churchill Livingstone 14.
81. NT Raikhlin, AA Baronin, EA Smirnova, et al. (2002) Ultrastructural criteria of malignancy of adrenal medullary tumor. Bull Exp Biol Med 134(1), 64-68.
82. J Yu and K Pacak (2002) Management of malignant pheochromocytoma. Endocrinologist 12 291-299.
83. RI Linnoila, HR Keiser, SM Steinberg, et al. (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features [see comments]. Hum Pathol 21(11), 1168-1180.
84. MR Clarke, RJ Weyant, CG Watson, et al. (1998) Prognostic markers in pheochromocytoma. Hum Pathol 29(5), 522-526.
85. I Modlin, J Farndon, A Shepherd, et al. (1979) Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg 66(7), 456-465.
86. J Henle (1990) Pathology of the adrenal glands. LM Roth,(Eds) Contemporary Issues in Surgical Pathology New York: Churchill Livingstone 14. cited by Lack EE
87. AG Pearse (1968) Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proc R Soc Lond B Biol Sci 170(18), 71-80.
88. JQ Trojanowski and VM Lee (1985) Expression of neurofilament antigens by normal and neoplastic human adrenal chromaffin cells. N Engl J Med 313(2), 101-104.
89. RJ Thompson, JF Doran, P Jackson, et al. (1983) PGP 9.5—a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 278(1–2), 224-228.
90. FE Bauer, GW Hacker, G Terenghi, et al. (1986) Localization and molecular forms of galanin in human adrenals: elevated levels in pheochromocytomas. J Clin Endocrinol Metab 63(6), 1372-1378.
91. K Mizuno, M Ojima, S Hashimoto, et al. (1985) Biochemical identification of renin in human pheochromocytoma. Res Commun Chem Pathol Pharmacol 50(3), 419-433.
92. C Gonzalez-Garcia and HR Keiser (1990) Angiotensin II and angiotensin converting enzyme binding in human adrenal gland and pheochromocytomas. J Hypertens 8(5), 433-441.
93. M Miettinen (1987) Synaptophysin and neurofilament proteins as markers for neuroendocrine tumors. Arch Pathol Lab Med 111(9), 813-818.
94. JH Sipple (1961) The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 31 163-166.
95. G Sarosi and RP Doe (1968) Familial occurrence of parathyroid adenomas, pheochromocytoma, and medullary carcinoma of the thyroid with amyloid stroma (Sipple's syndrome). Ann Intern Med 68(6), 1305-1309.
96. K Pacak, I Ilias, KT Adams, et al. (2005) Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257(1), 60-68.
97. ML Brandi, RF Gagel, A Angeli, et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12), 5658-5671.
98. LM Mulligan, JB Kwok, CS Healey, et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428), 458-460.
99. F Lore, F Talidis, G Di Cairano, et al. (2001) Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. J Intern Med 250(1), 37-42.
100. CA Koch, K Pacak and GP Chrousos (2002) The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87(12), 5367-5384.
101. RF Gagel, AH Tashjian Jr, T Cummings, et al. (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318(8), 478-484.
102. M Jadoul, JR Leo, MJ Berends, et al. (1989) Pheochromocytoma-induced hypertensive encephalopathy revealing MEN-IIa syndrome in a 13-year old boy. Implications for screening procedures and surgery. Horm Metab Res Suppl 21 46-49.
103. S Casanova, M Rosenberg-Bourgin, D Farkas, et al. (1993) Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol 38 531-537.
104. MR Khairi, RN Dexter, NJ Burzynski, et al. (1975) Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: multiple endocrine neoplasia type 3. Medicine (Baltimore) 54(2), 89-112.
105. C Eng, DP Smith, LM Mulligan, et al. (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3(2), 237-241.
106. JH Ross (2000) Pheochromocytoma. Special considerations in children. Urol Clin North Am 27(3), 393-402.
107. JA Carney, VL Go, H Gordon, et al. (1980) Familial pheochromocytoma and islet cell tumor of the pancreas. Am J Med 68(4), 515-521.
108. D Cameron, HM Spiro and L Landsberg (1978) Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II. N Engl J Med 299(3), 152-153.
109. DF Griffiths, GT Williams and ED Williams (1987) Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes. Q J Med 64(245), 769-782.
110. F Latif, K Tory, J Gnarra, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112), 1317-1320.
111. F Chen, T Kishida, M Yao, et al. (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlation with phenotype. Hum Mutat 5 66-75.
112. G Eisenhofer, MM Walther, TT Huynh, et al. (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86(5), 1999-2008.
113. V Kalff, B Shapiro, R Lloyd, et al. (1982) The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Intern Med 142(12), 2092-2098.
114. SD Colman and MR Wallace (1994) Neurofibromatosis type 1. Eur J Cancer 30A(13), 1974-1981.
115. T Jacks, TS Shih, EM Schmitt, et al. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7(3), 353-361.
116. MM Walther, J Herring, E Enquist, et al. (1999) von Recklinghausen's disease and pheochromocytomas. J Urol 162(5), 1582-1586.
117. D Astuti, F Douglas, TW Lennard, et al. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet 357(9263), 1181-1182.
118. BE Baysal, RE Ferrell, JE Willett-Brozick, et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454), 848-851.
119. K Astrom, JE Cohen, JE Willett-Brozick, et al. (2003) Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet 113(3), 228-237.
120. AP Gimenez-Roqueplo, J Favier, P Rustin, et al. (2002) Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87(10), 4771-4774.
121. D Astuti, F Latif, A Dallol, et al. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69(1), 49-54.
122. DE Benn, AP Gimenez-Roqueplo, JR Reilly, et al. (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91(3), 827-836.
123. B Havekes, EP Corssmit, JC Jansen, et al. (2007) Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. J Clin Endocrinol Metab 92(4), 1245-1248.
124. HP Neumann, C Pawlu, M Peczkowska, et al. (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8), 943-951.
125. HJ Timmers, K Pacak, J Bertherat, et al. (2008) Mutations associated with succinate dehydrogenase d-related malignant paragangliomas. Clin Endocrinol (Oxf) 4(68), 561-566.
126. F Schiavi, CC Boedeker, B Bausch, et al. (2005) Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294(16), 2057-2063.
127. M Mannelli, T Ercolino, V Giache, et al. (2007) Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet 44(9), 586-587.
128. M Peczkowska, A Cascon, A Prejbisz, et al. (2008) Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 4(2), 111-115.
129. G Eisenhofer, DS Goldstein, P Sullivan, et al. (2005) Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90 2068-2075.
130. G Eisenhofer, DS Goldstein, P Sullivan, et al. (2005) Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90(4), 2068-2075.
131. HJ Timmers, A Kozupa, G Eisenhofer, et al. (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92(3), 779-786.
132. WF Young Jr and AL Abboud (2006) Editorial: paraganglioma—all in the family. J Clin Endocrinol Metab 91(3), 790-792.
133. C Beldjord, F Desclaux-Arramond, M Raffin-Sanson, et al. (1995) The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 80(7), 2063-2068.
134. C Eng, PA Crossey, LM Mulligan, et al. (1995) Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32(12), 934-937.
135. MP Vargas, Z Zhuang, C Wang, et al. (1997) Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol 28(4), 411-415.
136. JA Carney (1983) The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: a five-year review. Medicine (Baltimore) 62(3), 159-169.
137. KB Margulies and SG Sheps (1988) Carney's triad: guidelines for management. Mayo Clin Proc 63(5), 496-502.
138. B Pasini, SR McWhinney, T Bei, et al. (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1), 79-88.
139. G Eisenhofer, J Lenders, W Linehan, et al. (1999) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340 1872-1879.
140. W Raber, W Raffesberg, M Bischof, et al. (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160(19), 2957-2963.
141. N Unger, C Pitt, IL Schmidt, et al. (2006) Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154(3), 409-417.
142. J Vaclavik, D Stejskal, B Lacnak, et al. (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 25(7), 1427-1431.
143. J Lenders, H Keiser, D Goldstein, et al. (1995) Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 123(2), 101-109.
144. WH de Jong, KS Graham, JC van der Molen, et al. (2007) Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem 53(9), 1684-1693.
145. JG Boyle, DF Davidson, CG Perry, et al. (2007) Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 92(12), 4602-4608.
146. CG Perry, AM Sawka, R Singh, et al. (2007) The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 66(5), 703-708.
147. G Eisenhofer (2003) Editorial: biochemical diagnosis of pheochromocytoma—is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 88(2), 550-552.
148. JW Lenders, JJ Willemsen, G Eisenhofer, et al. (2007) Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem 53(2), 352-354.
149. R Peaston, T Lennard and L Lai (1996) Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. J Clin Endocrinol Metab 81 1378-1384.
150. G Eisenhofer, DS Goldstein, MM Walther, et al. (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 88(6), 2656-2666.
151. PM Bouloux and D Perrett (1985) Interference of labetalol metabolites in the determination of plasma catecholamines by HPLC with electrochemical detection. Clin Chim Acta 150(2), 111-117.
152. JW Lenders, G Eisenhofer, I Armando, et al. (1993) Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39(1), 97-103.
153. M Roden, W Raffesberg, W Raber, et al. (2001) Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen. Clin Chem 47(6), 1061-1067.
154. K Pacak, G Eisenhofer, H Ahlman, et al. (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3(2), 92-102.
155. K Pacak, G Eisenhofer, H Ahlman, et al. (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium, October 2005. Nat Clin Pract Endocrinol Metab 3(2), 92-102.
156. A Grossman, K Pacak, A Sawka, et al. (2006) Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 1073 332-347.
157. SG Sheps and FT Maher (1966) Comparison of the histamine and tyramine hydrochloride tests in the diagnosis of pheochromocytoma. JAMA 195(4), 265-267.
158. EL Bravo and RW Gifford Jr (1984) Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311(20), 1298-1303.
159. E Bravo (1994) Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 15(3), 356-368.
160. RJ Sjoberg, KJ Simcic and GS Kidd (1992) The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 152(6), 1193-1197.
161. AM Lawrence (1967) Glucagon provocative test for pheochromocytoma. Ann Intern Med 66(6), 1091-1096.
162. E Grossman, D Goldstein, A Hoffman, et al. (1991) Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension 17 733-741.
163. K Pacak, DS Goldstein, JL Doppman, et al. (2001) A “pheo” lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 86(8), 3641-3646.
164. JW Lance and H Hinterberger (1976) Symptoms of pheochromocytoma, with particular reference to headache, correlated with catecholamine production. Arch Neurol 33(4), 281-288.
165. Y Ito, Y Fujimoto and T Obara (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16(4), 759-763.
166. SL Aronoff, E Passamani, BA Borowsky, et al. (1980) Norepinephrine and epinephrine secretion from a clinically epinephrine-secreting pheochromocytoma. Am J Med 69(2), 321-324.
167. J Bryant, J Farmer, LJ Kessler, et al. (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95(16), 1196-1204.
168. M Schlumberger, C Gicquel, J Lumbroso, et al. (1992) Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15 631-642.
169. E van der Harst, WW de Herder, RR de Krijger, et al. (2002) The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147(1), 85-94.
170. DS Goldstein, R Stull, G Eisenhofer, et al. (1986) Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. Ann Intern Med 105(6), 887-888.
171. H John, WH Ziegler, D Hauri, et al. (1999) Pheochromocytomas: can malignant potential be predicted? Urology 53(4), 679-683.
172. G Stenstrom and J Waldenstrom (1985) Positive correlation between urinary excretion of catecholamine metabolites and tumour mass in pheochromocytoma. Results in patients with sustained and paroxysmal hypertension and multiple endocrine neoplasia. Acta Med Scand 217(1), 73-77.
173. I Ilias and K Pacak (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89(2), 479-491.
174. T Scholz, G Eisenhofer, K Pacak, et al. (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4), 1217-1225.
175. Deleted in pages.
176. MM Grumbach, BM Biller, GD Braunstein, et al. (2003) Management of the clinically inapparent adrenal mass (“incidentaloma. Ann Intern Med 138(5), 424-429. ”)
177. J Miskulin, BL Shulkin, GM Doherty, et al. (2003) Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134(6), 918-922. discussion 22–23
178. S Maurea, A Cuocolo, JC Reynolds, et al. (1996) Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 40(4), 365-371.
179. JJ Mukherjee, PD Peppercorn, RH Reznek, et al. (1997) Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202(1), 227-231.
180. JFJ Schmedtje, S Sax, JL Pool, et al. (1987) Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am J Med 83 770-772.
181. G Prager, G Heinz-Peer, C Passler, et al. (2002) Can dynamic gadolinium-enhanced magnetic resonance imaging with chemical shift studies predict the status of adrenal masses? World J Surg 26(8), 958-964.
182. S Honigschnabl, S Gallo, B Niederle, et al. (2002) How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 41(2), 113-122.
183. B Shapiro, MD Gross and B Shulkin (2001) Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12(10), 469-475.
184. S Hoegerle, E Nitzsche, C Altehoefer, et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET—initial results. Radiology 222(2), 507-512.
185. BL Shulkin, NW Thompson, B Shapiro, et al. (1999) Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl Med 212 35-41.
186. J Epelbaum, J Bertherat, G Prevost, et al. (1995) Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80(6), 1837-1844.
187. L Von Moll, AJ McEwan, B Shapiro, et al. (1987) Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28(6), 979-988.
188. B Shapiro, JE Copp, JC Sisson, et al. (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26(6), 576-585.
189. T Nakatani, T Hayama, J Uchida, et al. (2002) Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 9(6), 1225-1227.
190. AN Van Der Horst-Schrivers, PL Jager, HM Boezen, et al. (2006) Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas—experience and meta-analysis. Anticancer Res 26(2B), 1599-1604.
191. HJ Timmers, A Kozupa, CC Chen, et al. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25(16), 2262-2269.
192. E van der Harst, WW de Herder, HA Bruining, et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86(2), 685-693.
193. KK Solanki, J Bomanji, J Moyes, et al. (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13(7), 513-521.
194. MD Lynn, B Shapiro, JC Sisson, et al. (1984) Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med 25(4), 436-440.
195. A Elgazzar, M Gelfand, L Washburn, et al. (1993) I-123 MIBG scintigraphy in adults. Clin Nucl Med 20(2), 147-152.
196. DS Goldstein, G Eisenhofer, BB Dunn, et al. (1993) Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22(7), 1961-1971.
197. I Ilias, J Yu, JA Carrasquillo, et al. (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88(9), 4083-4087.
198. BL Shulkin, DM Wieland, M Schwaiger, et al. (1992) PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33(6), 1125-1131.
199. HJ Timmers, M Hadi, JA Carrasquillo, et al. (2007) The effects of carbidopa on uptake of 6–18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48(10), 1599-1606.
200. O Warburg (1956) On the origin of cancer cells. Science 123(3191), 309-314.
201. G Kaltsas, M Korbonits, E Heintz, et al. (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86(2), 895-902.
202. K Pacak (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92(11), 4069-4079.
203. K Pacak (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92(11), 4069-4079.
204. M Mannelli (2006) Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073 405-416.
205. J.P.J. Nicholson JP Jr, ED Vaughn Jr, TG Pickering, et al. (1983) Pheochromocytoma and prazosin. Ann Intern Med 99(4), 477-479.
206. M Van Stratum, M Levarlet, JP Lambilliotte, et al. (1983) Use of labetalol during anesthesia for pheochromocytoma removal. Acta Anaesthesiol Belg 34(4), 233-240.
207. A Sjoerdsma, K Engelman, S Spector, et al. (1965) Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 2(7422), 1092-1094.
208. P Colson and J Ribstein (1991) [Simplified strategy for anesthesia of pheochromocytoma]. Ann Fr Anesth Reanim 10(5), 456-462.
209. R Perry, H Keiser, J Norton, et al. (1990) Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 212 621-628.
210. RS Briggs, AJ Birtwell and JE Pohl (1978) Hypertensive response to labetalol in phaeochromocytoma. Lancet 1(8072), 1045-1046.
211. H Vargas, L Kavoussi, D Bartlett, et al. (1997) Laparoscopic adrenalectomy: a new standard of care. Urology 49 673-678.
212. HN Winfield, BD Hamilton, EL Bravo, et al. (1998) Laparoscopic adrenalectomy: the preferred choice? A comparison to open adrenalectomy. J Urol 160(2), 325-329.
213. SG Sheps, NS Jiang, GG Klee, et al. (1990) Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc 65(1), 88-95.
214. G Stenstrom, I Ernest and LE Tisell (1988) Long-term results in 64 patients operated upon for pheochromocytoma. Acta Med Scand 223(4), 345-352.
215. L Amar, A Servais, AP Gimenez-Roqueplo, et al. (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90(4), 2110-2116.
216. RE Goldstein, JA O’Neill Jr, GW Holcomb 3rd, et al. (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229(6), 755-764.
217. D Kopf, PE Goretzki and H Lehnert (2001) Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 127(3), 143-155.
218. B Glodny, G Winde, R Herwig, et al. (2001) Clinical differences between benign and malignant pheochromocytomas. Endocr J 48(2), 151-159.
219. R Mornex, C Badet and L Peyrin (1992) Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J Endocrinol Invest 15(9), 643-649.
220. FM Brouwers, G Eisenhofer, JJ Tao, et al. (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91(11), 4505-4509.
221. J Mundschenk and H Lehnert (1998) Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 106(5), 373-376.
222. L Amar, E Baudin, N Burnichon, et al. (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92(10), 3822-3828.
223. M Stumvoll, A Fritsche, A Pickert, et al. (1997) Features of malignancy in a benign pheochromocytoma. Horm Res 48(3), 135-136.
224. Y Hosaka, LM Rainwater, CS Grant, et al. (1986) Pheochromocytoma: nuclear deoxyribonucleic acid patterns studied by flow cytometry. Surgery 100(6), 1003-1010.
225. HM Brown, RA Komorowski, SD Wilson, et al. (1999) Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86(8), 1583-1589.
226. WP Tormey, RJ Fitzgerald, G Thomas, et al. (2000) Catecholamine secretion and ploidy in phaeochromocytoma. Int J Clin Pract 54(8), 520-523.
227. F Rao, HR Keiser and DT O’Connor (2000) Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 36(6), 1045-1052.
228. L Yon, J Guillemot, M Montero-Hadjadje, et al. (2003) Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 88(6), 2579-2585.
229. EE Elder, D Xu, A Hoog, et al. (2003) KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16(3), 246-255.
230. KC Loh, PA Fitzgerald, KK Matthay, et al. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20(11), 648-658.
231. B Rose, KK Matthay, D Price, et al. (2003) High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98(2), 239-248.
232. M Lamarre-Cliche, AP Gimenez-Roqueplo, E Billaud, et al. (2002) Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 57(5), 629-634.
233. GJ Forster, MJ Engelbach, JJ Brockmann, et al. (2001) Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 28(12), 1743-1750.
234. SD Averbuch, CS Steakley, RC Young, et al. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109(4), 267-273.
235. MH Kulke, K Stuart, PC Enzinger, et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3), 401-406.
236. ZN Quezado, HR Keiser and MM Parker (1992) Reversible myocardial depression after massive catecholamine release from a pheochromocytoma. Crit Care Med 20(4), 549-551.
237. MA Taub, RC Osburne, LP Georges, et al. (1982) Malignant pheochromocytoma. Severe clinical exacerbation and release of stored catecholamines during lymphoma chemotherapy. Cancer 50(9), 1739-1741.
238. MZ Siddiqui, FE Von Eyben and G Spanos (1988) High-voltage irradiation and combination chemotherapy for malignant pheochromocytoma. Cancer 62(4), 686-690.
239. L Yu, AM Fleckman, M Chadha, et al. (1996) Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am J Clin Oncol 19(4), 389-393.
240. K Takahashi, N Ashizawa, T Minami, et al. (1999) Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 38(4), 349-354.
241. K Pacak, T Fojo, DS Goldstein, et al. (2001) Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 93(8), 648-649.
242. S Ohkawa, S Hirokawa, T Masaki, et al. (2002) [Examination of percutaneous microwave coagulation and radiofrequency ablation therapy for metastatic liver cancer]. Gan To Kagaku Ryoho 29(12), 2149-2151.
243. EW Fonkalsrud (1991) Pheochromocytoma in childhood. Prog Pediatr Surg 26 103-111.
244. B Havekes, JA Romijn, G Eisenhofer, et al. (2009) Update on pediatric pheochromocytoma. Pediatr Nephrol 24(5), 943-950.
245. DA Bloom and EW Fonkalsrud (1974) Surgical management of pheochromocytoma in children. J Pediatr Surg 9(2), 179-184.
246. MG Caty, AG Coran, M Geagen, et al. (1990) Current diagnosis and treatment of pheochromocytoma in children. Experience with 22 consecutive tumors in 14 patients. Arch Surg 125(8), 978-981.
247. M Barontini, G Levin and G Sanso (2006) Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 1073 30-37.
248. RR De Krijger, FH Van Nederveen, E Korpershoek, et al. (2006) Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci 1073 166-176.
249. AD Ludwig, DI Feig, ML Brandt, et al. (2007) Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg 194(6), 792-796. discussion 6–7
250. DM Hume (1960) Pheochromocytoma in the adult and in the child. Am J Surg 99 458-496.
251. BH Kaufman, RL Telander, JA van Heerden, et al. (1983) Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 18(6), 879-884.
252. VS Reddy, JA O’Neill Jr, GW Holcomb 3rd, et al. (2000) Twenty-five-year surgical experience with pheochromocytoma in children. Am Surg 66(12), 1085-1091. discussion 92
253. R Coutant, F Pein, C Adamsbaum, et al. (1999) Prognosis of children with malignant pheochromocytoma. Report of 2 cases and review of the literature. Horm Res 52(3), 145-149.
254. V Fonseca and PM Bouloux (1993) Phaeochromocytoma and paraganglioma. Baillieres Clin Endocrinol Metab 7(2), 509-544.
255. M Weise, D Merke, K Pacak, et al. (2002) Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 87(5), 1955-1960.
256. MA Harper, GA Murnaghan, L Kennedy, et al. (1989) Phaeochromocytoma in pregnancy. Five cases and a review of the literature. Br J Obstet Gynaecol 96(5), 594-606.
257. S Oishi and T Sato (1994) Pheochromocytoma in pregnancy: a review of the Japanese literature. Endocr J 41(3), 219-225.
258. JG Schenker and I Chowers (1971) Pheochromocytoma and pregnancy. Review of 89 cases. Obstet Gynecol Surv 26(11), 739-747.
259. SK Ahlawat, S Jain, S Kumari, et al. (1999) Pheochromocytoma associated with pregnancy: case report and review of the literature. Obstet Gynecol Surv 54(11), 728-737.
260. LM Brunt (2001) Phaeochromocytoma in pregnancy. Br J Surg 88(4), 481-483.
261. ME Molitch (1992) Endocrine emergencies in pregnancy. Baillieres Clin Endocrinol Metab 6(1), 167-191.
262. MJ Demeure, B Carlsen, D Traul, et al. (1998) Laparoscopic removal of a right adrenal pheochromocytoma in a pregnant woman. J Laparoendosc Adv Surg Tech A 8(5), 315-319.
263. SH Ein, B Shandling, D Wesson, et al. (1990) Recurrent pheochromocytomas in children. J Pediatr Surg 25(10), 1063-1065.
264. SZ Mitchell, JD Freilich, D Brant, et al. (1987) Anesthetic management of pheochromocytoma resection during pregnancy. Anesth Analg 66(5), 478-480.
265. MF James, KR Huddle, AD Owen, et al. (1988) Use of magnesium sulphate in the anaesthetic management of phaeochromocytoma in pregnancy. Can J Anaesth 35(2), 178-182.